| Plasma microRNAs as novel biomarkers for endometriosis and endometriosis-associated ovarian cancer S Suryawanshi, AM Vlad, HM Lin, G Mantia-Smaldone, R Laskey, MJ Lee, ... Clinical Cancer Research 19 (5), 1213-1224, 2013 | 279 | 2013 |
| MUC1 immunobiology: from discovery to clinical applications AM Vlad, JC Kettel, NM Alajez, CA Carlos, OJ Finn Advances in immunology 82, 249-294, 2004 | 262 | 2004 |
| Cisplatin-induced immune modulation in ovarian cancer mouse models with distinct inflammation profiles S Grabosch, M Bulatovic, F Zeng, T Ma, L Zhang, M Ross, J Brozick, ... Oncogene 38 (13), 2380-2393, 2019 | 220 | 2019 |
| The mechanism of unresponsiveness to circulating tumor antigen MUC1 is a block in intracellular sorting and processing by dendritic cells EM Hiltbold, AM Vlad, P Ciborowski, SC Watkins, OJ Finn The Journal of Immunology 165 (7), 3730-3741, 2000 | 207 | 2000 |
| Complex carbohydrates are not removed during processing of glycoproteins by dendritic cells: processing of tumor antigen MUC1 glycopeptides for presentation to major … AM Vlad, S Muller, M Cudic, H Paulsen, L Otvos Jr, FG Hanisch, OJ Finn The Journal of experimental medicine 196 (11), 1435-1446, 2002 | 201 | 2002 |
| Inhibition of histone lysine-specific demethylase 1 elicits breast tumor immunity and enhances antitumor efficacy of immune checkpoint blockade Y Qin, SN Vasilatos, L Chen, H Wu, Z Cao, Y Fu, M Huang, AM Vlad, B Lu, ... Oncogene 38 (3), 390-405, 2019 | 177 | 2019 |
| Complement pathway is frequently altered in endometriosis and endometriosis-associated ovarian cancer S Suryawanshi, X Huang, E Elishaev, RA Budiu, L Zhang, SH Kim, ... Clinical Cancer Research 20 (23), 6163-6174, 2014 | 139 | 2014 |
| Upregulation of the ATR‐CHEK1 pathway in oral squamous cell carcinomas RA Parikh, LJ Appleman, JE Bauman, M Sankunny, DW Lewis, A Vlad, ... Genes, Chromosomes and Cancer 53 (1), 25-37, 2014 | 84 | 2014 |
| Targeted treatment of recurrent platinum-resistant ovarian cancer: current and emerging therapies GM Mantia-Smaldone, RP Edwards, AM Vlad Cancer management and research, 25-38, 2011 | 84 | 2011 |
| Form and pattern of MUC1 expression on T cells activated in vivo or in vitro suggests a function in T‐cell migration I Correa, T Plunkett, A Vlad, A Mungul, J Candelora‐Kettel, JM Burchell, ... Immunology 108 (1), 32-41, 2003 | 79 | 2003 |
| Tumor-associated MUC1 glycopeptide epitopes are not subject to self-tolerance and improve responses to MUC1 peptide epitopes in MUC1 transgenic mice SO Ryan, AM Vlad, K Islam, J Gariépy, OJ Finn Walter de Gruyter 390 (7), 611-618, 2009 | 75 | 2009 |
| Immunization of chimpanzees with tumor antigen muc1 mucin tandem repeat peptide elicits both helper and cytotoxict-cell responses SM Barratt-Boyes, A Vlad, OJ Finn Clinical Cancer Research 5 (7), 1918-1924, 1999 | 75 | 1999 |
| A phase II trial of intraperitoneal interleukin-2 in patients with platinum-resistant or platinum-refractory ovarian cancer AM Vlad, RA Budiu, DE Lenzner, Y Wang, JA Thaller, K Colonello, ... Cancer immunology, immunotherapy 59, 293-301, 2010 | 73 | 2010 |
| Robust gene expression and mutation analyses of RNA-sequencing of formalin-fixed diagnostic tumor samples S Graw, R Meier, K Minn, C Bloomer, AK Godwin, B Fridley, A Vlad, ... Scientific reports 5 (1), 12335, 2015 | 71 | 2015 |
| Soluble MUC1 and serum MUC1-specific antibodies are potential prognostic biomarkers for platinum-resistant ovarian cancer RA Budiu, G Mantia-Smaldone, E Elishaev, T Chu, J Thaller, K McCabe, ... Cancer Immunology, Immunotherapy 60, 975-984, 2011 | 61 | 2011 |
| Human mucin MUC1 RNA undergoes different types of alternative splicing resulting in multiple isoforms L Zhang, A Vlad, C Milcarek, OJ Finn Cancer Immunology, Immunotherapy 62, 423-435, 2013 | 59 | 2013 |
| A conditional mouse model for human MUC1-positive endometriosis shows the presence of anti-MUC1 antibodies and Foxp3+ regulatory T cells RA Budiu, I Diaconu, R Chrissluis, A Dricu, RP Edwards, AM Vlad Disease models & mechanisms 2 (11-12), 593-603, 2009 | 59 | 2009 |
| Glycoprotein tumor antigens for immunotherapy of breast cancer AM Vlad, OJ Finn Breast disease 20 (1), 73-79, 2004 | 50 | 2004 |
| Cancer-associated MSC drive tumor immune exclusion and resistance to immunotherapy, which can be overcome by Hedgehog inhibition S Cascio, C Chandler, L Zhang, S Sinno, B Gao, S Onkar, TC Bruno, ... Science advances 7 (46), eabi5790, 2021 | 43 | 2021 |
| Immunobiology of human mucin 1 in a preclinical ovarian tumor model RA Budiu, E Elishaev, J Brozick, M Lee, RP Edwards, P Kalinski, AM Vlad Oncogene 32 (32), 3664-3675, 2013 | 38 | 2013 |
